-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Sees Significant Growth in Short Interest
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Sees Significant Growth in Short Interest
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Get Rating) was the target of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 875,700 shares, a growth of 24.3% from the November 30th total of 704,700 shares. Approximately 3.5% of the shares of the stock are sold short. Based on an average daily volume of 1,390,000 shares, the days-to-cover ratio is presently 0.6 days.
Wall Street Analysts Forecast Growth
ABOS has been the subject of several recent analyst reports. BTIG Research upped their price target on Acumen Pharmaceuticals from $15.00 to $22.00 and gave the stock a "buy" rating in a research note on Wednesday, October 5th. Credit Suisse Group dropped their price target on Acumen Pharmaceuticals from $17.00 to $16.00 and set an "outperform" rating for the company in a research note on Tuesday, November 15th.
Get Acumen Pharmaceuticals alerts:Institutional Trading of Acumen Pharmaceuticals
Hedge funds have recently modified their holdings of the company. Commodore Capital LP purchased a new stake in Acumen Pharmaceuticals during the 3rd quarter valued at $11,033,000. Great Point Partners LLC purchased a new stake in Acumen Pharmaceuticals during the 1st quarter valued at $3,630,000. BlackRock Inc. raised its holdings in Acumen Pharmaceuticals by 23.2% during the 1st quarter. BlackRock Inc. now owns 3,831,321 shares of the company's stock valued at $14,980,000 after buying an additional 721,651 shares during the period. Vanguard Group Inc. raised its holdings in Acumen Pharmaceuticals by 122.5% during the 1st quarter. Vanguard Group Inc. now owns 1,234,771 shares of the company's stock valued at $4,828,000 after buying an additional 679,798 shares during the period. Finally, Deep Track Capital LP raised its holdings in Acumen Pharmaceuticals by 34.5% during the 1st quarter. Deep Track Capital LP now owns 2,599,098 shares of the company's stock valued at $10,162,000 after buying an additional 666,058 shares during the period. 67.92% of the stock is owned by hedge funds and other institutional investors.
Acumen Pharmaceuticals Stock Up 0.6 %
Shares of ABOS opened at $5.40 on Friday. Acumen Pharmaceuticals has a 1 year low of $3.02 and a 1 year high of $10.97. The business's 50 day simple moving average is $6.14 and its 200-day simple moving average is $5.97.Acumen Pharmaceuticals (NASDAQ:ABOS – Get Rating) last issued its quarterly earnings data on Monday, November 14th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.01. Research analysts predict that Acumen Pharmaceuticals will post -1.01 EPS for the current fiscal year.
Acumen Pharmaceuticals Company Profile
(Get Rating)
Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers.
Featured Stories
- Get a free copy of the StockNews.com research report on Acumen Pharmaceuticals (ABOS)
- MarketBeat: Week in Review 12/26 – 12/30
- The Dogs Of Tech: It's Time For A Bite Of These Stocks
- Does This Acquisition Make Microsoft a Bear Market Buy?
- Should You Warm up to Generac Stock for the Winter?
- Is Kintara Therapeutics A Hidden Gem?
Receive News & Ratings for Acumen Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acumen Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Acumen制药公司(纳斯达克:ABOS-GET评级)是空头股数12月份大幅增长的目标。截至12月15日,空头股数共有87.57万股,比11月30日的70.47万股增长24.3%。大约3.5%的股票被卖空。以日均成交量1,390,000股计算,目前天数与回补比率为0.6天。
华尔街分析师预测经济增长
ABOS一直是最近几份分析师报告的主题。BTIG Research将Acumen PharmPharmticals的目标价从15.00美元上调至22.00美元,并在10月5日星期三的一份研究报告中给予该股“买入”评级。瑞士信贷集团在11月15日星期二的一份研究报告中将Acumen PharmPharmticals的目标价从17.00美元下调至16.00美元,并为该公司设定了“跑赢大盘”的评级。
到达Acumen制药公司警报:Acumen制药的制度性交易
对冲基金最近调整了对该公司的持股。Commodore Capital LP在第三季度购买了Acumen制药公司的新股份,价值11,033,000美元。Great Point Partners LLC在第一季度购买了Acumen制药公司的新股份,价值3,630,000美元。贝莱德股份有限公司在第一季度增持了23.2%的Acumen制药股份。贝莱德股份有限公司在此期间又购买了721,651股,目前持有该公司3,831,321股股票,价值14,980,000美元。先锋集团在第一季度增持了Acumen PharmPharmticals的股份122.5%。先锋集团现在持有1,234,771股该公司股票,价值4,828,000美元,在此期间又购买了679,798股。最后,深轨资本有限公司在第一季度将其在Acumen PharmPharmticals的持股增加了34.5%。Deep Track Capital LP现在拥有该公司2,599,098股股票,价值10,162,000美元,在此期间又购买了666,058股。67.92%的股票由对冲基金和其他机构投资者持有。
Acumen制药类股上涨0.6%
上周五,ABOS的股价开盘报5.40美元。Acumen PharmPharmticals的一年低点为3.02美元,一年高位为10.97美元。该业务的50日简单移动均线切入位为6.14美元,200日简单移动均线切入位为5.97美元。Acumen PharmPharmticals(纳斯达克:ABOS-GET评级)最近一次发布季度收益数据是在11月14日星期一。该公司公布本季度每股收益(EPS)为0.26美元,比普遍预期的0.27美元高出0.01美元。研究分析师预测,Acumen制药公司本财年的每股收益将达到1.01欧元。
Acumen制药公司简介
(获取评级)
Acumen制药公司是一家临床阶段的生物制药公司,发现和开发治疗阿尔茨海默病的疗法。该公司专注于开发一种靶向免疫治疗候选药物ACU193,这是一种人源化单抗,正处于I期临床阶段,用于靶向可溶性淀粉样β寡聚体。
专题报道
- 免费获取StockNews.com关于Acumen制药的研究报告(ABOS)
- MarketBeat:回顾一周12/26-12/30
- 科技狗:是时候咬一口这些股票了
- 这笔收购会让微软成为熊市买入者吗?
- 你应该热身到Generac股票过冬吗?
- 金塔拉治疗公司是一颗隐藏的宝石吗?
获得《Acumen PharmPharmticals Daily》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Acumen制药和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧